Cambium Bio Secures A$10.85M To Initiate Phase 3 Trial Of Elate Ocular For Dry Eye Disease

Cambium Bio secured an A$10.85 million funding package to initiate a pivotal Phase 3 trial of Elate Ocular for moderate-to-severe dry eye disease. The financing advances a key late-stage clinical-development milestone and is a positive catalyst for the company, though its impact is likely concentrated in Cambium Bio shares.